Ionis Pharmaceuticals, Inc. (IONS): Price and Financial Metrics


Ionis Pharmaceuticals, Inc. (IONS)

Today's Latest Price: $51.13 USD

0.89 (1.77%)

Updated Nov 27 1:00pm

Add IONS to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

IONS Stock Summary

  • With a price/earnings ratio of 97.4, Ionis Pharmaceuticals Inc P/E ratio is greater than that of about 91.31% of stocks in our set with positive earnings.
  • The price/operating cash flow metric for Ionis Pharmaceuticals Inc is higher than 87.36% of stocks in our set with a positive cash flow.
  • In terms of volatility of its share price, IONS is more volatile than merely 11.85% of stocks we're observing.
  • If you're looking for stocks that are quantitatively similar to Ionis Pharmaceuticals Inc, a group of peers worth examining would be ACRS, RESN, CUE, BLUE, and TBPH.
  • IONS's SEC filings can be seen here. And to visit Ionis Pharmaceuticals Inc's official web site, go to www.ionispharma.com.

IONS Stock Price Chart Interactive Chart >

Price chart for IONS

IONS Price/Volume Stats

Current price $51.13 52-week high $66.22
Prev. close $50.24 52-week low $39.32
Day low $50.01 Volume 415,900
Day high $51.19 Avg. volume 905,479
50-day MA $48.44 Dividend yield N/A
200-day MA $53.37 Market Cap 7.15B

Ionis Pharmaceuticals, Inc. (IONS) Company Bio


Ionis Pharmaceuticals, Inc., a RNA-targeted drug discovery and development company, focuses on developing drugs for patients with severe and rare diseases. The company was formerly known as Isis Pharmaceuticals, Inc. and changed its name to Ionis Pharmaceuticals, Inc. in December 2015. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.

IONS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$51.13$20.77 -58%

We started the process of determining a valid price forecast for Ionis Pharmaceuticals Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Ionis Pharmaceuticals Inc ranked in the 28th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Ionis Pharmaceuticals Inc, consider:

  • 89% of the company's capital comes from equity, which is greater than 74.27% of stocks in our cash flow based forecasting set.
  • Ionis Pharmaceuticals Inc's effective tax rate, as measured by taxes paid relative to net income, is at 18 -- greater than 71.53% of US stocks with positive free cash flow.
  • The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than 49.09% of stocks in its sector (Healthcare).


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-59%
1%-58%
2%-58%
3%-57%
4%-57%
5%-56%

Want more companies with a valuation profile/forecast similar to that of Ionis Pharmaceuticals Inc? See HSIC, PCRX, CDNA, ENTA, and HAPP.


IONS Latest News Stream


Event/Time News Detail
Loading, please wait...

IONS Latest Social Stream


Loading social stream, please wait...

View Full IONS Social Stream

Latest IONS News From Around the Web

Below are the latest news stories about Ionis Pharmaceuticals Inc that investors may wish to consider to help them evaluate IONS as an investment opportunity.

Ionis Chief Scientific Officer Frank Bennett receives Lifetime Achievement Award from Oligonucleotide Therapeutics Society

CARLSBAD, Calif., Oct. 1, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that Frank Bennett, Ph.D., Ionis' executive vice president and chief scientific officer, has been awarded the 2020 Lifetime Achievement Award by…

PR Newswire | October 1, 2020

Ionis and Genuity Science announce agreement designed to rapidly translate genomic insights into therapeutics

BOSTON and CARLSBAD, Calif., Oct. 1, 2020 /PRNewswire/ -- Genuity Science, a genomics and data insights organization and Ionis Pharmaceuticals (NASDAQ: IONS), the leader in antisense therapeutics, today announced a broad, multi-year collaboration aimed at accelerating the discovery and…

PR Newswire | October 1, 2020

Global RNA Interference Market To See Astonishing Growth By 2027|Covid 19 Impact Analysis By Arcturus Therapeutics, Inc., Arrowhead Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., Ionis Pharmaceuticals

This research report acknowledges the presentation segments of the global market. The market was classified in terms of presentation in the next piece. The report highlights substantial market growth trends and dynamics, including limitations, drivers and opportunities. A number of

OpenPR | September 30, 2020

Ionis treatment for Alexander disease receives orphan drug designation from U.S. FDA

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, announced today that the U.S. Food and Drug Administration…

PR Newswire | September 30, 2020

AKCEA INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akcea Therapeutics, Inc. - AKCA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akcea Therapeutics, Inc. (NasdaqGS: AKCA) to Ionis Pharmaceuticals, Inc. (NasdaqGS: IONS). Under the terms of the proposed transaction, shareholders of Akcea will receive only $18.15 in cash for each share of Akcea that they own. KSF is seeking to determine whether this consideration and the process that led t

Business Wire | September 4, 2020

Read More 'IONS' Stories Here

IONS Price Returns

1-mo 8.90%
3-mo -6.18%
6-mo -11.34%
1-year -20.06%
3-year -7.86%
5-year -17.37%
YTD -15.36%
2019 11.75%
2018 7.48%
2017 5.16%
2016 -22.77%
2015 0.31%

Continue Researching IONS

Want to see what other sources are saying about Ionis Pharmaceuticals Inc's financials and stock price? Try the links below:

Ionis Pharmaceuticals Inc (IONS) Stock Price | Nasdaq
Ionis Pharmaceuticals Inc (IONS) Stock Quote, History and News - Yahoo Finance
Ionis Pharmaceuticals Inc (IONS) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.859 seconds.